Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephen Salloway

Neurology Providence, RI Medical Doctor

NPI 1891701116 CMS profile 177036

345 Blackstone Blvd, Providence, RI 02906

Open in the dashboard

General payments

$329,256

250 records reported · program years 2019–2025

Research payments

$28,938

Paid to them · 17 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$15,765,675 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Stephen Salloway of Providence, RI is reported in the CMS Open Payments database as having received $329,256 across 250 general payments and $28,938 in research payments paid to them. Separately, studies naming them as principal investigator received $15,765,675 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $91,000 60
2025 Research $1,298 2
2024 General $90,047 53
2024 Research $301 1
2023 General $39,373 47
2023 Research $3,141 5
2022 General $49,974 35
2022 Research $4,103 2
2021 General $12,762 8
2021 Research $648 1
2020 General $24,545 19
2020 Research $5,378 4
2019 General $21,554 28
2019 Research $14,069 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephen Salloway
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Stephen Salloway were reported at $91,000. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Stephen Salloway Neurology median Middle half National median
2019 $21,554 $474 $118–$2,177 $163
2020 $24,545 $367 $82–$2,309 $114
2021 $12,762 $438 $104–$2,547 $132
2022 $49,974 $442 $103–$2,388 $149
2023 $39,373 $464 $119–$2,312 $160
2024 $90,047 $468 $119–$2,323 $164
2025 $91,000 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $98,661 45 payments
  2. Eli Lilly and Company $41,403 54 payments
  3. Novo Nordisk Inc $34,653 24 payments
  4. Biogen, Inc. $34,054 28 payments
  5. F. Hoffmann-La Roche AG $21,433 18 payments
  6. Eisai Inc. $20,267 19 payments
  7. Merck Sharp & Dohme Corporation $11,677 10 payments
  8. Avid Radiopharmaceuticals, Inc. $8,883 5 payments
  9. Janssen Global Services, LLC $6,932 10 payments
  10. Genentech, Inc. $6,420 3 payments
  11. Other $44,873 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $240,196 92 payments
  2. Travel and Lodging $58,153 80 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $26,735 11 payments
  4. Food and Beverage $4,173 67 payments
Products named General payments · program years 2019–2025
  1. KISUNLA $51,546 17 payments
  2. EMGALITY $6,314 4 payments
  3. ADUHELM $5,708 6 payments
  4. None $3,510 1 payment
  5. ADLARITY $2,240 1 payment
  6. Non-Covered Product $1,725 2 payments
  7. VIZAMYL $1,250 1 payment
  8. API015 $25 1 payment
  9. AMYVID $22 1 payment
  10. Leqembi $17 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $12,959 5 payments
  2. Biogen, Inc. $11,031 3 payments
  3. F. Hoffmann-La Roche AG $4,741 8 payments
  4. Genentech, Inc. $208 1 payment

Records

267 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Rhode Island

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record